Rizatriptan Benzoate Tablet
Product Images NDC 71335-2536

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-2536). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352536)

Each tablet contains 7.265 mg of Rizatriptan Benzoate, USP equivalent to 5 mg Rizatriptan. The medication is recommended to be stored at 20° to 25°C (68° to 77°F) and kept in a tight, light-resistant container. This pharmaceutical product is available in a package with 30 tablets and should be kept out of the reach of children. The medication is to be dispensed by pharmacists with the patient package inserts. Manufacturer information: Bryant Ranch Prepack, Inc. and Aurobindo Pharma Limited.*

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

This text discusses a Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours in pooled studies involving placebo and rizatriptan benzoate in doses of 5 mg and 10 mg. The data is derived from four placebo-controlled outpatient trials, indicating the efficacy of rizatriptan benzoate in treating headaches. Patients who did not achieve headache response within 2 hours or received additional treatment were censored at the 2-hour mark for the analysis.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

This text provides a figure showcasing the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines over 24 hours following the initial dose in pooled studies 1, 2, 3, and 4. The data presented includes the percentage of patients opting for a second dose at various time intervals. The plot is based on data from 4 placebo-controlled outpatient clinical trials and includes patients who had a headache response at 2 hours as well as those who did not respond to the initial dose. Remedication within 2 hours post-dose was not allowed.*

FDA Label Image

Figure3 (Rizatriptan Fig3)

This description is not available.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.